Personalized drug discovery at lightspeed

(Cet article n'est disponible qu'en anglais)
HiFiBiO Therapeutics and CSEM are collaborating to develop and manufacture single-cell microfluidics that will enable novel immunotherapies for the treatment of cancer and autoimmune diseases. A new paradigm is emerging thanks to the integration of deep biological expertise and data intelligence.